# Amping up With PemJAK

> **NCT07283822** · PHASE2 · RECRUITING · sponsor: **Seda S. Tolu** · enrollment: 53 (estimated)

## Conditions studied

- Non-Hodgkin Lymphoma
- Hodgkin Disease Lymphoma
- Non-Hodgkin Lymphoma Refractory/ Relapsed
- Hodgkin Disease Recurrent
- Gray Zone Lymphoma
- Peripheral T-cell Lymphoma
- Cutaneous T-Cell Lymphomas
- Primary Mediastinal B Cell Lymphoma

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07283822
- **Lead sponsor:** Seda S. Tolu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-03
- **Primary completion:** 2028-01
- **Final completion:** 2029-01
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2025-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07283822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07283822, "Amping up With PemJAK". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07283822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*